Here is what has been moving in glioblastoma research and advocacy over the past 48 hours — from a personalized vaccine showing real early results, to a surprising hormone finding, a new approach to treating tumors that come back, and a promising early-stage lab discovery.

A Personalized Vaccine Is Showing Early Promise in Glioblastoma

Researchers at Washington University School of Medicine in St. Louis ran a Phase 1 clinical trial testing a personalized cancer vaccine called GNOS-PV01 in nine adults newly diagnosed with glioblastoma. Each patient’s vaccine was custom-built around proteins unique to their own tumor — called neoantigens — so the immune system could learn to recognize and attack those specific cancer cells. The vaccine was given starting about ten weeks after surgery, alongside the standard treatment. All but one patient who was on immune-suppressing steroids showed an immune response; two-thirds had no cancer progression at six months, and two-thirds survived at least one year. The results were published in the journal Nature Cancer on May 12.

Why it matters

This trial focused on a subtype called MGMT-unmethylated GBM, which does not respond well to standard chemotherapy — one of the hardest versions of this disease to treat. Nine patients is a tiny number, and Phase 1 trials are mainly designed to check safety rather than prove something works at scale. Larger studies will be needed before this vaccine could become widely available. Still, seeing an immune response in nearly all participants and improved early survival numbers in a patient group with so few options is genuinely encouraging.

Source: WashU Medicine / Nature Cancer

Testosterone Linked to 38% Lower Risk of Death in Men with Glioblastoma

A Cleveland Clinic team analyzed records from more than 1,300 men diagnosed with glioblastoma and found that those who happened to be taking supplemental testosterone for unrelated reasons — such as low testosterone levels — had a 38% lower risk of death compared to those who were not. To understand why, the researchers also ran experiments in mouse models and found that when androgen hormones like testosterone are reduced, the brain’s stress-response system goes into overdrive, which actually accelerates tumor growth. The study was published in Nature.

Why it matters

This is an observational study, meaning it tracked what happened in patients over time rather than randomly assigning people to take testosterone or not — which makes it harder to prove cause and effect directly. The researchers are not recommending testosterone supplements as a GBM treatment yet, and no one should start or stop any supplement without talking with their care team first. What makes this noteworthy is the size of the dataset and the supporting lab evidence together. For male patients already taking testosterone for other reasons, it is worth a conversation with your oncologist.

Source: NIH / Nature

Targeted Radiation Seeds Show 100% Local Tumor Control in Small Recurrent GBM Trial

Alpha Tau Medical reported interim results from its REGAIN trial, which is testing a technology called Alpha DaRT in patients with recurrent glioblastoma — cancer that has come back after initial treatment. Alpha DaRT works by implanting tiny radioactive seeds directly into the tumor; the seeds release high-energy alpha particles over a short distance, aiming to destroy the tumor while limiting damage to surrounding healthy brain tissue. Of the first three patients treated (between December 2025 and March 2026), two achieved a complete response — meaning no measurable tumor on imaging — and one had stable disease with a shrinking tumor. No unexpected serious safety events were reported.

Why it matters

Recurrent GBM is one of the most difficult situations a patient and family can face, with very few options offering meaningful benefit. Three patients is far too small a number to draw firm conclusions, but two complete responses in patients who had already failed prior radiation is the kind of early signal that warrants continued attention. The REGAIN trial plans to enroll up to ten patients total, and larger data will be needed before anything definitive can be said.

Source: GlobeNewswire / Alpha Tau Medical

University of Tulsa Patents Compounds That Target GBM Cells While Sparing Healthy Brain Tissue

Biochemistry researchers at the University of Tulsa filed a patent on more than 30 new compounds built from a modified version of memantine, a drug already approved for Alzheimer’s disease. In lab tests, one of these compounds showed strong potency against glioblastoma cells with no observable effect on normal brain cells under the same conditions. The compound may also be able to cross the blood-brain barrier, a critical challenge for any brain cancer treatment. The compounds outperformed temozolomide — the standard frontline chemotherapy for GBM — in early cell-based tests.

Why it matters

This research is at a very early stage — lab tests on cells, not animal studies or human trials, and years away from any clinical use. But selectively killing cancer cells without harming healthy tissue nearby is precisely the challenge that makes brain cancer so hard to treat, and a compound that appears to do both — while also crossing the blood-brain barrier — is the kind of early finding worth following. The fact that it is derived from an already-approved drug may also help streamline parts of the safety review process further down the road.

Source: PR Newswire / University of Tulsa

Sending care and strength to everyone in the GBM community this week.